Patient randomisations

0

Patient randomisations with suspected or proven COVID-19

0

Available interventions in 10 domains

0

Total patients

0

Patients with suspected or proven COVID-19

0

Active sites in Europe

EU numbers – updated 28-Nov-2022

REMAP-CAP

A Randomised, Embedded, Multi-factorial, Adaptive Platform
trial for Community-Acquired Pneumonia

The study

The Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) was conceived after the 2009 Influenza AH1N1 (“Swine flu”) outbreak. During that pandemic and previous ones, the research response has been largely absent. REMAP-CAP was set up as an Adaptive Platform Trial embedded in clinical care that allows multiple therapies to be evaluated at the same time under a master protocol. In Europe, the trial is currently running in 15 countries.